Streetbeat News

Analyst Ratings

WBA

Walgreens Boots Alliance's stock has been upgraded from Neutral to Overweight by JP Morgan, leading to a rise in the company's shares.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:14 am

ENTA

HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on Enanta Pharma (NASDAQ:ENTA) but lowers the price target from $48 to $30.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:07 am

XPL

HC Wainwright & Co. analyst Heiko Ihle maintains a 'Buy' rating on Solitario Resources (AMEX:XPL) but lowers the price target from $0.9 to $0.8.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:03 am

IONS

B of A Securities analyst Jason Gerberry has upgraded Ionis Pharmaceuticals (NASDAQ:IONS) from Underperform to Neutral and raised the price target from $33 to $52.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:02 am

WBA

JP Morgan analyst Lisa Gill has upgraded Walgreens Boots Alliance (NASDAQ:WBA) from Neutral to Overweight and raised the price target from $27 to $30.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:00 am

LIVN

Needham analyst Mike Matson has maintained a 'Buy' rating on LivaNova (NASDAQ:LIVN) but lowered the price target from $71 to $62.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 10:54 am

MCD

Barclays analyst Jeffrey Bernstein maintains an Overweight rating on McDonald's (NYSE:MCD) but has lowered the price target from $345 to $315.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 10:48 am

EEFT

Needham analyst Mayank Tandon has reiterated a 'Buy' rating on Euronet Worldwide (NASDAQ:EEFT) and maintained a price target of $115.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 10:47 am

KRUS

Barclays analyst Jeffrey Bernstein has maintained an Equal-Weight rating on Kura Sushi USA (NASDAQ:KRUS) but lowered the price target from $95 to $67.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 10:46 am

RVMD

Needham analyst Ami Fadia maintains a Buy rating on Revolution Medicines (NASDAQ:RVMD) and raises the price target from $34 to $36.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 10:45 am